Pacira(PCRX) GlobeNewswire News Room·2025-02-13 17:35Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has significantly impacted its stock price following the invalidation of a key patent [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for investors affected by alleged securities fraud between August 2, 2023, and August 8, 2024 [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from 11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].